Clinical Trial Update: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequencing of cobimetinib plus vemurafenib followed by anti-PD-L1 immunotherapy in unresectable or metastatic BRAF V600 mutant melanoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)
• anti-PD-L1 antibody

Snippet

Sponsor: University Hospital, Essen | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED